• A Difficult Case of Calcineurin Inhibitor Neurotoxicity Post-Haploidentical HCT With a Successful Novel Solution: Cytotoxic T-Lymphocyte-Associated Protein 4-Immunoglobulin Blockade for GVHD Prophylaxis
• A network meta-analysis of the effectiveness of different basic preconditioning regiments in allogeneic hematopoietic stem cell transplantation
• A strategy to reconstitute immunity without GVHD via adoptive allogeneic Tscm therapy
• A Tender RIC for the Unfit: A Novel 4 Gy TBI-based Conditioning Followed by Two-step Haploidentical Stem Cell transplant, Results of a Prospective Trial
• Abatacept for acute graft-versus-host disease prophylaxis after unrelated donor hematopoietic cell transplantation
• Advances in second hematopoietic stem cell transplantation
• Allogeneic blood or marrow transplantation using haploidentical grandchildren donors and post-transplant cyclophosphamide-based graft-versus-host disease prophylaxis
• Allogeneic Hematopoietic Stem Cell Transplantation in Immunodeficiency-Centromeric Instability-Facial Dysmorphism (ICF) Syndrome: an EBMT/ESID Inborn Errors Working Party Study
• An enterococcal phage-derived enzyme suppresses graft-versus-host disease
• Analysis of the efficacy and prognostic factors of allogeneic hematopoietic stem cell transplantation in patients with myelodysplastic syndrome with blastomycosis and survival comparison of different subtypes after the WHO 2022 reclassification
• Anterior Segment Optical Coherence Tomography Imaging of the Lacrimal Gland in Patients With Chronic Ocular Graft-Vs-Host Disease
• Anti-CD7 allogeneic WU-CART-007 in patients with relapsed/refractory T-cell acute lymphoblastic leukemia/lymphoma: a phase 1/2 trial
• Anti-thymocyte globulin combined with post-transplantation cyclophosphamide reduce graft-versus-host disease in hematopoietic stem cell transplantation for pediatric leukemia
• Application of CD25 and CTLA4 gene transcription levels in early prediction of acute graft-versus-host disease
• Associations between acute and chronic graft-versus-host disease
• Better clinical outcomes and lower triggering of inflammatory cytokines for allogeneic hematopoietic cell transplant recipients treated in home care versus hospital isolation - the Karolinska experience
• Causes and characteristics of pre-engraftment mortality after allogeneic hematopoietic stem cell transplantation
• CD47;Rag2;IL-2rγ triple knock-out mice pre-conditioning with busulfan could be a novel platform for generating hematopoietic stem cells engrafted humanized mice
• Challenges with sirolimus experimental data to inform QSP model of post-transplantation cyclophosphamide regimens
• Chinese expert consensus on the diagnosis and treatment of acute graft-versus-host disease after hematopoietic stem cell transplantation (2024)
• Chronic graft-versus-host disease: Unresolved complication or ancient history?
• Clinical analysis on the impact of pretransplant iron overload on allogeneic hematopoietic stem cell transplantation for patients with acquired severe aplastic anemia in pediatric
• Clinical and Economic Impact of CMV Infection in Allogeneic Hematopoietic Stem Cell Transplantation: Perspectives from a Middle-Income Nation
• Clinical characteristics and outcomes of immunocompromised critically ill patients with cytomegalovirus end-organ disease: a multicenter retrospective cohort study
• Clinical characteristics and outcomes of overt gastrointestinal bleeding in children undergoing haploidentical hematopoietic stem cell transplantation: a single-center retrospective analysis
• Combination of reduced post-transplant cyclophosphamide and early tacrolimus initiation increases the incidence of chronic graft-versus-host disease in human leukocyte antigen-haploidentical peripheral blood stem-cell transplantation
• Comparative analysis of reduced toxicity conditioning regimens between fludarabine plus melphalan and fludarabine plus busulfex in adult patients with acute lymphoblastic leukemia
• Comparing the risk of severe oral mucositis associated with methotrexate as graft-versus host-disease prophylaxis to other immunosuppressive prophylactic agents in hematopoietic cell transplantation: a systematic review and meta-analysis
• Cyclophosphamide and horse anti-thymocyte globulin versus fludarabine, reduced cyclophosphamide and rabbit anti-thymocyte globulin conditioning regimen for allogeneic hematopoietic stem cell transplantation from matched sibling donors in patients with acq
• Cytology or Multiparameter Flow Cytometry Positivity in the Cerebrospinal Fluid Before Transplantation is Predictive of Poor Outcomes After Allotransplantation in Acute Myeloid Leukemia Patients
• Diagnosis of Cutaneous Acute Graft-Versus-Host Disease Through Circulating Plasma miR-638, miR-6511b-5p, miR-3613-5p, miR-455-3p, miR-5787, and miR-548a-3p as Prospective Noninvasive Biomarkers Following Allogeneic Hematopoietic Stem Cell Transplantation
• Donor and recipient hematopoietic stem and progenitor cells mobilization in liver transplantation patients
• Dual roles of CD11b⁺CD33⁺HLA-DR^-/lowCD14^- myeloid-derived suppressor cells with a granulocytic morphology following allogeneic hematopoietic stem cell transplantat
• Early intervention with oral mucosal barrier Protective agents in chronic oral graft-versus-host disease: a retrospective cohort study
• Early Tapering of Cyclosporine Is Feasible in Haploidentical Stem Cell Transplantation: A Single Center Experience
• Effect of donor and recipient HLA mismatched locus on the prognosis of childhood with leukemia after umbilical cord blood transplantation
• Effect of early post-hematopoietic stem cell transplant tacrolimus concentration on transplant outcomes in pediatric recipients: One facility's ten-year experience of immunosuppression with tacrolimus
• Elafin level in lichen planus
• Exanthematous Eruption in a Patient With Known Chronic Graft-vs-Host Disease and Recent Measles Vaccination
• Expansion and characterization of immune suppressive CD56(bright)Perforin(-) regulatory-like natural killer cells in chronic graft-versus-host disease
• Graft Versus Host Disease Prophylaxis in Matched Donor Stem Cell Transplantation: Post-transplantation Cyclophosphamide Combinations Versus Methotrexate/Tacrolimus
• Graft-versus-host disease in patients with bone marrow transplants: A retrospective study analyzing outcomes and healthcare burden in US hospitals
• GVHD: bile duct stem cells under attack
• Haploidentical versus HLA-matched sibling donor HCT with PTCy prophylaxis: HLA factors and donor age considerations
• Haploidentical Versus Mismatched Unrelated Donor Hematopoietic Cell Transplantation: HLA Factors and Donor Age Considerations
• hPMSCs prevent erythrocytes dysfunction caused by graft versus host disease via promoting GSH synthesis
• Human placental mesenchymal stromal cells promote the formation of CD8(+)CD122(+)PD-1(+)Tregs via CD73/Foxo1 to alleviate liver injury in graft-versus-host disease mice
• Icariin protects against acute graft-versus-host disease while preserving graft-versus-leukemia activity after allogeneic hematopoietic stem cell transplantation
• Immune-related adverse events associated with mogamulizumab: a comprehensive review of the literature
• Impact of Antifungal Prophylaxis Continuation or Discontinuation After Allogeneic Hematopoietic Cell Transplant on the Incidence of Invasive Mold Infection
• Impact of dexamethasone on transplant-related mortality in pediatric patients: a multi-site, propensity score-weighted, retrospective assessment
• Impact of Race and Ethnicity on Outcomes After Umbilical Cord Blood Transplantation
• Impact of the Type of Tyrosine Kinase Inhibitor (imatinib or dasatinib) Used Before allo-HCT on Outcome of Patients with Philadelphia-Positive Acute Lymphoblastic Leukemia. A Study on Behalf of the Acute Leukemia Working Party of the EBMT
• Initiation of Haploidentical Stem Cell Transplantation With Post-Transplant Cyclophosphamide in Children: A Low-Middle-Income Country Institutional Experience
• Innate and Adaptive Immune Responses in Intestinal Transplant Rejection: Through the Lens of Inflammatory Bowel and Intestinal Graft-Versus-Host Diseases
• invariant Natural Killer T cell therapy as a novel therapeutic approach in hematological malignancies
• Is HLA-E with its receptors an immune checkpoint or an antigenic determinant in allo-HCT?
• Late-Onset Noninfectious Pulmonary Complications After Allogeneic Hematopoietic Stem Cell Transplantation: Single-Center Experience
• Lck Function and Modulation: Immune Cytotoxic Response and Tumor Treatment More Than a Simple Event
• Lower incidence of grade II-IV acute Graft-versus-Host-Disease in pediatric patients recovering with high Vdelta2+ T cells after allogeneic stem cell transplantation with unmanipulated bone marrow grafts: a prospective single-center cohort study
• Mapping the genetic landscape establishing a tumor immune microenvironment favorable for anti-PD-1 response in mice and humans
• MASCC/ISOO Clinical Practice Statement: Management of oral manifestations of chronic graft-versus-host-disease
• MASCC/ISOO Clinical Practice Statement: The risk of secondary oral cancer following hematopoietic cell transplantation
• Melphalan Dose in Combination with Fludarabine Affects GI Toxicity and GVHD after Allogeneic Transplantation in Acute Myeloid Leukemia and Myelodysplastic Syndromes
• Mesenchymal stem cells preconditioned with a TLR5 agonist enhanced immunoregulatory effect through M2 macrophage polarization in a murine graft-versus-host disease model
• Minor histocompatibility antigens to predict, monitor or manipulate GvL and GvHD after allogeneic hematopoietic cell transplantation
• Multi-omics analysis reveals a feedback loop amplifying immune responses in acute graft-versus-host disease due to imbalanced gut microbiota and bile acid metabolism
• Nanoparticles loaded with IL-2 and TGF-β promote transplantation tolerance to alloantigen
• New investigational drugs for steroid-refractory acute graft-versus-host disease: a review of the literature
• Novel MAGIC composite scores using both clinical symptoms and biomarkers best predict treatment outcomes of acute GVHD
• Older MRD vs. younger MUD in patients older than 50 years with AML in remission using post-transplant cyclophosphamide
• Oral Mucositis and Nutritional Status in Children Who Underwent Hematopoietic Cell Transplantation: A Comparison Between Nonmalignant and Malignant Primary Diseases
• Outcomes of haplo-cord versus dual cord transplants: a single-center retrospective analysis
• Outcomes with low dose anti-thymocyte globulin based graft versus host disease prophylaxis after mismatched unrelated donor allogeneic hematopoietic cell transplantation
• Patient-reported physical well-being predicts good long-term survival of hematopoietic stem cell transplantation
• Phototherapy for the treatment of cutaneous graft-versus-host disease: A systematic review
• Post-transplantation cyclophosphamide and cyclosporine A versus methotrexate and cyclosporine A for graft-versus-host disease prophylaxis after allogeneic peripheral stem cell transplantation in adult acute myeloid leukemia patients
• Reconstitution of norovirus-specific T cell responses following hematopoietic stem cell transplantation in patients with inborn errors of immunity and chronic norovirus infection
• Rejection resistant CD30.CAR-modified Epstein-Barr virus-specific T cells as an off-the-shelf platform for CD30⁺ lymphoma
• Retrospective analysis of the incidence and outcome of late acute and chronic graft-versus-host disease-an analysis from transplant centers across Europe
• Ruxolitinib in treatment-naive or corticosteroid-refractory paediatric patients with chronic graft-versus-host disease (REACH5): interim analysis of a single-arm, multicentre, phase 2 study
• Ruxolitinib Plus Basiliximab Therapy for Steroid-Refractory Acute Graft-Versus-Host Disease in Unrelated Cord Blood Transplantation: A Large-Scale Study
• Ruxolitinib: a game changer in paediatric chronic graft-versus-host disease management?
• Severity and organ distribution of graft-versus-host disease with post-transplant cyclophosphamide versus calcineurin inhibitor plus methotrexate/mycophenolate mofetil or sirolimus in allogenic HLA-matched or single-allele mismatched stem cell transplanta
• Surrogates of endothelial injury predict survival after post-transplant cyclophosphamide
• Survival impact of response within the first year in a multicenter prospective observational study of chronic GVHD in a Japanese cohort
• Systemic diseases affecting the GI tract: A review of clinical and histopathologic manifestations
• The Consequences of HLA Screening in the Prevention of Graft-Versus-Host Disease in Living Donor Liver Transplantation
• The effect of ADAMTS13 on graft-versus-host disease
• The Immunotherapy of Acute Myeloid Leukemia: A Clinical Point of View
• Total Body Irradiation and Fludarabine with Post-Transplant Cyclophosphamide for Mismatched Related or Unrelated Donor HCT
• Transplantation in Adult Patients with Epstein-Barr Virus-Associated Hemophagocytic Lymphohistiocytosis: Yes or No?
• Traversing the bench to bedside journey for iNKT cell therapies
• Trends in allogeneic transplantation for favorable risk acute myeloid leukemia in first remission: a longitudinal study of >15 years from the ALWP of the EBMT
• Type II innate lymphoid cell plasticity contributes to impaired reconstitution after allogeneic hematopoietic stem cell transplantation
• Unravelling the potential of TIM-3 gene polymorphism in allogeneic hematopoietic stem cell transplantation - a preliminary study
• Unrelated donor transplantation with post-transplant cyclophosphamide versus ATG for myelodysplastic neoplasms
• Update on Maintenance Immunosuppression in Intestinal Transplantation
• Vedolizumab plus basiliximab as second-line therapy for steroid-refractory lower gastrointestinal acute graft-versus-host disease
• Young (<35 years) haploidentical versus old (≥35 years) mismatched unrelated donors and vice versa for allogeneic stem cell transplantation with post-transplant cyclophosphamide in patients with acute myeloid leukemia in first remission: a study on